California State Teachers Retirement System Has $13.67 Million Stock Position in Penumbra, Inc. $PEN

California State Teachers Retirement System grew its holdings in Penumbra, Inc. (NYSE:PEN - Free Report) by 0.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,286 shares of the company's stock after buying an additional 299 shares during the period. California State Teachers Retirement System owned 0.11% of Penumbra worth $13,667,555 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. AlphaGrep UK Ltd bought a new stake in Penumbra during the 2nd quarter valued at $365,000. Turner Financial Group Inc. purchased a new stake in shares of Penumbra in the second quarter worth approximately $279,000. Nykredit A S purchased a new stake in shares of Penumbra during the second quarter valued at about $489,000. Two Sigma Securities LLC purchased a new stake in shares of Penumbra in the second quarter worth about $855,000. Finally, Harvest Management LLC raised its holdings in Penumbra by 219.4% in the 2nd quarter. Harvest Management LLC now owns 57,487 shares of the company's stock valued at $18,152,000 after acquiring an additional 39,487 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Penumbra Stock Down 0.4%

NYSE:PEN traded down $1.15 during midday trading on Tuesday, hitting $318.71. 277,389 shares of the company were exchanged, compared to its average volume of 617,979. The company has a current ratio of 5.75, a quick ratio of 3.86 and a debt-to-equity ratio of 0.01. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The company has a fifty day simple moving average of $321.53 and a 200 day simple moving average of $325.32. The company has a market capitalization of $12.55 billion, a PE ratio of 78.32, a price-to-earnings-growth ratio of 2.18 and a beta of 0.70.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.16 by ($0.28). Penumbra had a net margin of 10.67% and a return on equity of 10.50%. The company had revenue of $390.05 million for the quarter, compared to analyst estimates of $389.64 million. During the same quarter in the prior year, the firm earned $0.86 EPS. The company's revenue for the quarter was up 14.9% compared to the same quarter last year. As a group, equities analysts anticipate that Penumbra, Inc. will post 4.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PEN. Evercore restated an "outperform" rating and issued a $320.00 target price on shares of Penumbra in a report on Monday, July 6th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $374.00 target price on shares of Penumbra in a research report on Thursday, June 11th. Weiss Ratings reiterated a "hold (c)" rating on shares of Penumbra in a research report on Friday, July 17th. Finally, Zacks Research raised Penumbra from a "strong sell" rating to a "hold" rating in a research report on Monday, August 24th. Three research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $367.07.

Penumbra Company Profile

Penumbra, Inc NYSE: PEN is a medical device company that develops, manufactures and markets products designed to treat neurovascular, vascular and other medical conditions. Its technologies are used by physicians in minimally invasive procedures, including the removal of blood clots, treatment of aneurysms and management of vascular disorders.

The company's product portfolio includes aspiration and mechanical thrombectomy systems for ischemic stroke and pulmonary embolism, embolization devices for aneurysms and other vascular conditions, and access and peripheral vascular products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.